Do you want to read an article? Please log in or register.
Microwave treatment of renal cell carcinoma adjacent to renal sinus
Genitourinary Cancer
Related content
Genitourinary Cancer
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
Eur J Cancer.
Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G
doi: 10.1016/j.ejca.2017.06.030.
Genitourinary Cancer
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Lancet Oncol
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI
doi: 10.1016/S1470-2045(20)30436-8
Genitourinary Cancer
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Eur Urol.
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S
doi: 10.1016/j.eururo.2017.03.037.
SPECIAL REPORT
Skin Cancer
Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2
Genitourinary Cancer
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
Target Oncol.
Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE
doi: 10.1007/s11523-017-0487-4.
Genitourinary Cancer
Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma
Eur Urol.
Tosoian JJ, Feldman AS, Abbott MR, Mehra R, Tiemeny P, Wolf JS Jr, Stone S, Wu S, Daignault-Newton S, Taylor JMG, Wu CL, Morgan TM
doi: 10.1016/j.eururo.2020.08.032.
COMMENTED
Genitourinary Cancer
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Navani V, Heng DYC
doi: 10.1001/jamaoncol.2021.4337
ASCO® 2019
Genitourinary Cancer
Renal Cell Carcinoma
Rini et al. 2019. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Oral presentation presented at: ASCO 2019 Congress; May 31–June 4; Chicago, IL, USA.
RECOMMENDED
Genitourinary Cancer
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Lancet Oncol.
Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC
doi: 10.1016/S1470-2045